Navigation Links
Bellicum Pharmaceuticals Announces $3.75 Million in Financing
Date:10/10/2007

Receives Emerging Technology Fund Award from the State of Texas in the

Amount of $1.45 Million as well as $2.3 Million in Seed Funding

HOUSTON, Oct. 10 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced it was awarded $1.45 Million by the State of Texas' Emerging Technology Fund. Additionally, the company announced seed financing of $2.3 million. The combined investment will be used for development of the company's lead product candidate, BP-GMAX-CD1 for patients with advanced, androgen independent prostate cancer. The financing will allow the completion of preclinical development and initiation of a Phase 1/2 clinical trial.

Bellicum Pharmaceuticals, Inc. is focused on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer. Bellicum's BP-GMAX-CD1 lead product candidate is a novel dendritic cell vaccine for the treatment of prostate cancer. This vaccine incorporates a drug-activated CD40 gene, which acts as a pharmacologically regulated switch to boost the potency and enhance the durability of the anti- cancer immune response (see, Hanks, et al, Nature Medicine 2005, 11:130).

"We are honored to receive this award from the Emerging Technology Fund," stated CEO Tom Farrell. "It's a testament to the strength of our science and the potential of the company to have a meaningful impact on the lives of cancer patients. The State's financial support, together with the seed capital provided by local angel investors, allows us to advance our lead product into the clinic, where we have a near-term opportunity to demonstrate human proof of concept."

The Texas Emerging Technology Fund (TETF) is a $200 million initiative created by the Texas Legislature in 2005 at the Governor's request. A 17- member advisory committee of high-tech leaders, entrepreneurs and research experts reviews potential TETF projects and recommends funding for projects to the Governor, Lieutenant Governor and Speaker of the House. To date, the TETF has allocated $76.8 million in grant funds to Texas companies and universities. For more information on the TETF, please visit http://www.emergingtechfund.com.

Kevin Slawin, M.D., Bellicum Founder and Director of the Vanguard Urologic Institute and the Texas Prostate Center, and Director of Urology at Memorial Hermann Hospital - TMC, has dedicated his career to battling the significant problem of prostate cancer that men face. "I'm excited to see our hard work reaching this important milestone and poised to begin testing in advanced prostate cancer patients here in Houston in the New Year", Slawin commented. "While vaccines currently in development by others are extremely well tolerated, their efficacy has been marginal at best. BP-GMAX-CD1 eliminates the shortcomings of these other approaches, and if it works for prostate cancer patients, we will have a platform that can be adapted to target any type of cancer."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is focused on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer. Founded in July 2004 by Professors Kevin M. Slawin, M.D. and David M. Spencer, Ph.D., the company is developing clinical products based on novel and powerful vaccine strategies developed at Baylor College of Medicine. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in late stage preclinical development for patients with advanced, androgen independent prostate cancer. BP-GMAX-CD1 and follow-on product candidates have been successfully tested in mouse models and human dendritic cells. The company owns or has in-licensed certain key technologies, and Chief Executive Officer Thomas J. Farrell has assembled a team of seasoned clinical, regulatory, quality and CMC consultants to advance product candidates into human clinical trials. Bellicum is a client of the Houston Technology Center. For more information, visit http://www.bellicum.com


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 2017 , ... If you are thinking of a visit to San Francisco , fall ... the perfect time to visit. , Business Architecture Associates is pleased to offer 5 days ... as a 4-½ day package for individuals, and as 4-½ day corporate package for up ...
(Date:5/24/2017)... ... May 24, 2017 , ... Technique, technique, technique – with a ... lifting weights for strength training and exercise or simply lifting heavy objects, advises Dr. ... position is everything,” Dr. Chang says. “Improper technique in lifting anything heavy or an ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and medical device sectors, today announced the winners of its 3rd Annual ELITE ... the most influential people in the healthcare industry today. , Out of more ...
(Date:5/23/2017)... Newport Beach, CA (PRWEB) , ... May 23, 2017 , ... ... Capital Partners was honored to serve earlier this month as a Guest Speaker and ... by the British Royal Family and Common Purpose. , Walter Schindler ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: HRC), ... 100,000 square feet to its Welch Allyn campus. ... commitment to bring more than 100 new jobs to ... Allyn has maintained a significant presence for more than ... new positions, a large portion of which will be ...
(Date:5/4/2017)... SAN DIEGO , May 4, 2017  The ... Clinical and Scientific Meeting— OBP Medical , a leading ... announced the launch of a new extra-small size and ... ER-SPEC vaginal specula. Already available in small, ... sizes makes OBP Medical,s line of single-use lighted specula ...
(Date:5/3/2017)... 3, 2017 A Catheterization Laboratory is ... healthcare facility. Commonly referred to as cath lab, ... diagnostic imaging technology to give physicians visual access ... these spaces, a team of physicians perform life-saving ... coronary intervention, congenital heart defect closure, stenotic heart ...
Breaking Medicine Technology: